MALAT1 and prostate adenocarcinoma: To further validate the same, we performed a Kaplan–Meier survival analysis by stratifying the TCGA-PRAD patients based on their MALAT1 median expression into high (≥median, n = 248) and low (≤median, n = 250) groups.